Table 5.
Relative risks and 95% confidence intervals of breast cancer according to 1 SD increase in natural log transformed plasma measures and polymorphisms
| MTHFR 677C>T | CC Cases/Controls (166/360) |
CT Cases/Controls (225/397) |
XT Cases/Controls (n=51/119) |
P for interaction* | CT+TT Cases/Controls (n=276/516) |
P for interaction† |
|---|---|---|---|---|---|---|
| Plasma folate, ng/mL | 1.03 (0.83 – 1.27) | 1.06 (0.88 – 1.28) | 2.01 (1.21 – 3.34) | 0.28 | 1.21 (1.02 – 1.42) | 0.13 |
| Plasma vitamin B12, pg/ml | 1.12 (0.90 – 1.39) | 1.22 (1.01 – 1.47) | 1.72 (1.08 – 2.72) | 0.45 | 1.30(1.10 – 1.53) | 0.04 |
| Plasma pyridoxal 5’- phosphate, pmol/ml | 0.92 (0.74 – 1.15) | 1.11 (0.92 – 1.35) | 1.78(1.14 – 2.77) | 0.01 | 1.18 (1.00 – 1.40) | 0.05 |
| Plasma homocysteine, nmol/ml | 1.03 (0.83 – 1.27) | 1.05 (0.88 – 1.26) | 0.91 (0.59 – 1.39) | 0.25 | 1.02 (0.87 – 1.20) | 0.67 |
| Plasma cysteine, nmol/ml | 0.95 (0.77 – 1.18) | 1.16(0.97 – 1.39) | 1.33 (0.89 – 1.98) | 0.82 | 1.16(0.99 – 1.36) | 0.01 |
| Plasma cysteinylglycine, nmol/ml | 0.97 (0.80 – 1.18) | 1.04 (0.87 – 1.25) | 1.28 (0.82 – 1.98) | 0.21 | 1.04 (0.89 – 1.23) | 0.15 |
| MTHFR1298A>C | AA Cases/Controls (279/530) |
AC Cases/Controls (n=266/511) |
CC Cases/Controls (n=50/100) |
P for interaction* | AC+CC Cases/Controls (n=316/611) |
P for interaction† |
| Plasma folate, ng/mL | 1.22 (1.04 – 1.44) | 1.02 (0.86 – 1.20) | 1.18(0.70 – 1.99) | 0.03 | 1.03 (0.88 – 1.20) | 0.09 |
| Plasma vitamin B12, pg/ml | 1.34 (1.15 – 1.56) | 1.10 (0.93 – 1.29) | 2.09 (1.16 – 3.76) | 0.001 | 1.15 (0.99 – 1.34) | 0.07 |
| Plasma pyridoxal 5’- phosphate, pmol/ml | 1.12 (0.96 – 1.30) | 1.10(0.93 – 1.29) | 1.06 (0.66 – 1.71) | 0.01 | 1.10(0.94 – 1.28) | 0.93 |
| Plasma homocysteine, nmol/ml | 0.98 (0.84 – 1.14) | 0.97 (0.83 – 1.14) | 1.04 (0.65 – 1.68) | 0.31 | 0.97 (0.83 – 1.12) | 0.83 |
| Plasma cysteine, nmol/ml | 1.15 (0.98 – 1.35) | 0.96 (0.81 – 1.14) | 1.35 (0.82 – 2.22) | 0.23 | 0.96 (0.82 – 1.12) | 0.02 |
| Plasma cysteinylglycine, nmol/ml | 1.01 (0.86 – 1.19) | 0.96 (0.81 – 1.13) | 1.13 (0.73 – 1.75) | 0.77 | 0.99 (0.85 – 1.15) | 0.83 |
| DHFR WT>del | WT/WT Cases/Controls (n= 188/377) |
WT/del Cases/Controls (n=280/576) |
del/del Cases/Controls (n= 125/205) |
P for interaction* | WT/del+del/del Cases/Controls (n=405/781) |
P for interaction† |
| Plasma folate, ng/mL | 1.10(0.89 – 1.37) | 1.05 (0.90 – 1.23) | 1.09 (0.85 – 1.40) | 0.75 | 1.07 (0.94 – 1.22) | 0.38 |
| Plasma vitamin B12, pg/ml | 1.18(0.96 – 1.44) | 1.09 (0.93 – 1.27) | 1.50(1.16 – 1.93) | 0.44 | 1.22 (1.07 – 1.38) | 0.88 |
| Plasma pyridoxal 5’-phosphate, pmol/ml | 1.08 (0.88 – 1.34) | 1.09 (0.93 – 1.26) | 0.99 (0.77 – 1.27) | 0.50 | 1.07 (0.94 – 1.21) | 0.73 |
| Plasma homocysteine, nmol/ml | 1.01 (0.83 – 1.24) | 0.99 (0.84 – 1.15) | 0.95 (0.75 – 1.20) | 0.85 | 0.97 (0.85 – 1.10) | 0.54 |
| Plasma cysteine, nmol/ml | 1.03 (0.83 – 1.27) | 1.02 (0.87 – 1.19) | 1.13 (0.87 – 1.47) | 0.37 | 1.06 (0.93 – 1.20) | 0.72 |
| Plasma cysteinylglycine, nmol/ml | 1.04 (0.84 – 1.29) | 1.03 (0.88 – 1.20) | 0.90 (0.70 – 1.17) | 0.69 | 0.99 (0.87 – 1.13) | 0.66 |
*
P for interaction compares all three genotypes using ordinal coding
†
P for interaction compares any minor allele to no minor allele